Tag: strategies

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach around USD 2,943.92 Million by 2034, at a CAGR of 16.65% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Artivion Inc., Athersys Inc., Baxter International Inc., Cellular Logistics Inc., Elutia Inc., Heartseed Inc., Medtronic Plc, Merck kGaA, Mesoblast Ltd., Neoolife Inc., Tejiin Limited, Terumo Corporation, and W.L. Gore & Associates, Inc and others.

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

BOCA RATON, FL, July 21, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it now holds 999,999 SOL and SOL equivalents on its balance sheet.

– Results Reflect Continued Financial Strength and Deleveraging –

Tel Aviv, Israel, July 21, 2025 (GLOBE NEWSWIRE) -- Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced the appointment of Mr. Eliyahu Zamir as the Company’s new Chief Executive Officer, effective as of August 1, 2025. Mr. Eliyahu Zamir will replace Mr. Viki Hakmon, who will step down from his position as the Company’s Chief Executive Officer, effective as of July 31, 2025. On July 21, 2025, Mr. Hakmon also resigned from the Board of Directors, effective immediately. Mr. Hakmon’s resignation did not result from any disagreements with the Company or the Board of Directors and he will continue to support the Company as a consultant of the Company’s subsidiary, Fort Products Limited.

TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) announced (i) the release of the results of its previously announced separate offers (the “Offers”) to purchase for cash up to the Maximum Purchase Amount (as defined in the offer to purchase dated July 11, 2025 relating to the Notes (the “Offer to Purchase”)) of its outstanding senior notes of the series listed in the table below (collectively, the “Notes”), and (ii) that it has amended the Offers by increasing the Maximum Purchase Amount from C$400,000,000 to an amount sufficient to accept all tendered (1) 4.25% Senior Notes due 2049, (2) 2.90% Senior Notes due 2030 and (3) 3.30% Senior Notes due 2029, in each case in full, and approximately C$300 million principal amount of the 3.25% Senior Notes due 2029.